NCT03002649View on ClinicalTrials.gov

Study of Tofacitinib in Refractory Dermatomyositis

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

September 30, 2020

Study Completion Date

September 30, 2020

Conditions
Dermatomyositis
Interventions
DRUG

Tofacitinib

Tofacitinib comes as an extended-release (XR) (long-acting) tablet to take by mouth. The extended-release tablet is usually taken with or without food once daily.

Trial Locations (1)

21224

Johns Hopkins University, Baltimore

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Johns Hopkins University

OTHER

NCT03002649 - Study of Tofacitinib in Refractory Dermatomyositis | Biotech Hunter | Biotech Hunter